TO CHECK THE PAIN RELIVING ACTION OF ROPIVACAINE VERSUS LEVOBUPIVACAINE IN PATIENT UNDERGOING BREAST SURGERY.
- Conditions
- Malignant neoplasm of breast,
- Registration Number
- CTRI/2018/11/016311
- Lead Sponsor
- Department of Anesthesiology kidwai Cancer Institute
- Brief Summary
Adequate post operative analgesia with minimal side effects is major concern of post anaesthesia care.
Ropivacaine known to be significantly lower toxic effect than racemic Bupivacaine, it is less potent than Bupivacaine when used at equal concentration.
Levobupivacine the s enantiomer of racemic Bupivacaine is associated with greater safety with regard to cardiotoxic and neurotoxicity. It is also found that it is equipotent to racemic Bupivacaine.
This prospective study is proposed to compare analgesic efficacy in modified radical mastectomy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 60
ASA 1 and 2 Consenting patient Weight 50-70kg.
Patient refusal History of allergy Severe renal liver cardiac and pulmonary dysfunction Unable to comprehend VAS scale.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analgesic efficacy VAS scale Post operatively 0min, 15min, 30min, 45min, 60min,90min,2,4,8,12,16,20 and 24hours.
- Secondary Outcome Measures
Name Time Method Requirements of rescue analgesia Incidence and severity of side effect
Trial Locations
- Locations (1)
KIDWAI CANCER INSTITUTE
🇮🇳Bangalore, KARNATAKA, India
KIDWAI CANCER INSTITUTE🇮🇳Bangalore, KARNATAKA, IndiaJEAN HANNAH PHILIPPrincipal investigator7293564005jeanhannah91@gmail.com